Literature DB >> 22112476

Biologic characteristics of premalignant breast disease.

Kimberly Cole1, Maria Tabernero, Karen S Anderson.   

Abstract

Breast cancer is the second leading cause of cancer death in women in the United States. While mammography and breast magnetic resonance imaging (MRI) improve detection of early disease, there remains an unmet need for biomarkers for risk stratification, early detection, prediction, and disease prognosis. A number of early breast lesions, from atypical hyperplasias to carcinomas in situ, are associated with an increased risk of developing subsequent invasive breast carcinoma. The recent development of genomic, epigenomic, and proteomic tools for tissue biomarker detection, including array CGH, RNA expression microarrays, and proteomic arrays have identified a number of potential biomarkers that both identify patients at increased risk, as well as provided insights into the pathology of early breast cancer development. This chapter focuses on the detection and application of tissue and serum biomarkers for the identification and risk stratification of early breast cancer lesions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22112476      PMCID: PMC3432637          DOI: 10.3233/CBM-2011-0187

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  197 in total

Review 1.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

Review 2.  Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes.

Authors:  M Esteller
Journal:  Eur J Cancer       Date:  2000-12       Impact factor: 9.162

3.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

4.  LOH analyses of premalignant and malignant lesions of human breast: frequent LOH in 8p, 16q, and 17q in atypical ductal hyperplasia.

Authors:  M Amari; A Suzuki; T Moriya; K Yoshinaga; G Amano; H Sasano; N Ohuchi; S Satomi; A Horii
Journal:  Oncol Rep       Date:  1999 Nov-Dec       Impact factor: 3.906

Review 5.  MicroRNA control of signal transduction.

Authors:  Masafumi Inui; Graziano Martello; Stefano Piccolo
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03-10       Impact factor: 94.444

6.  Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer.

Authors:  U Lehmann; B Hasemeier; M Christgen; M Müller; D Römermann; F Länger; H Kreipe
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

7.  Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study.

Authors:  Y Umekita; T Takasaki; H Yoshida
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.

Authors:  P Lenner; F Wiklund; S O Emdin; C Arnerlöv; C Eklund; G Hallmans; H Zentgraf; J Dillner
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

9.  Autoantibodies as potential biomarkers for breast cancer.

Authors:  Li Zhong; Kun Ge; Jin-chi Zu; Long-hua Zhao; Wei-ke Shen; Jian-fei Wang; Xiao-gang Zhang; Xu Gao; Wanping Hu; Yun Yen; Kemp H Kernstine
Journal:  Breast Cancer Res       Date:  2008-05-07       Impact factor: 6.466

10.  The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.

Authors:  K Aigner; B Dampier; L Descovich; M Mikula; A Sultan; M Schreiber; W Mikulits; T Brabletz; D Strand; P Obrist; W Sommergruber; N Schweifer; A Wernitznig; H Beug; R Foisner; A Eger
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

View more
  5 in total

1.  The biology of incipient, pre-invasive or intraepithelial neoplasia.

Authors:  William E Grizzle; Sudhir Srivastava; Upender Manne
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 2.  Evolution of Premalignant Disease.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

3.  Immunoexpression analysis and prognostic value of BLCAP in breast cancer.

Authors:  Irina Gromova; Pavel Gromov; Niels Kroman; Vera Timmermans Wielenga; Ronald Simon; Guido Sauter; José M A Moreira
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

4.  Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer.

Authors:  Meredith C Henderson; Alan B Hollingsworth; Kelly Gordon; Michael Silver; Rao Mulpuri; Elias Letsios; David E Reese
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

5.  Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.

Authors:  Kinga Walaszek; Elyse E Lower; Piotr Ziolkowski; Georg F Weber
Journal:  Br J Cancer       Date:  2018-10-24       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.